Bay Area's Global Blood Therapeutics Terminates Lung Disease Program Post author:Sam Post published:October 22, 2017 Post category:BioPharma The company is shuttering its GBT440 program to treat idiopathic pulmonary fibrosis (IPF). Source: BioSpace You Might Also Like Rumor Alert: AstraZeneca PLC CEO to Become Teva's New Leader July 12, 2017 Strongbridge Biopharma Banks $53 Million Financing From July 16, 2017 Beleaguered Axovant Begins Cutting Jobs While Exiting CEO Gets $2.6M+ Severance Package February 14, 2018
Beleaguered Axovant Begins Cutting Jobs While Exiting CEO Gets $2.6M+ Severance Package February 14, 2018